10-Q: Tenon Medical Reports Q3 2024 Results, Revenue Declines Amidst Restructured Sales Operations

Tenon Medical's Q3 2024 results show a decrease in revenue compared to the same period last year, alongside a reduction in operating expenses, as the company navigates a sales restructuring and reimbursement challenges.

Summary

• Tenon Medical reported a net loss of $3.184 million for the three months ended September 30, 2024, compared to a net loss of $3.332 million for the same period in 2023.
• Revenue decreased to $887,000 in Q3 2024 from $944,000 in Q3 2023, primarily due to a 15% decrease in surgical procedures using the Catamaran System.
• The company's gross profit was $418,000 in Q3 2024, down from $535,000 in Q3 2023.
• Operating expenses decreased to $3.633 million in Q3 2024 from $3.913 million in Q3 2023, with reductions in research and development and sales and marketing expenses.
• For the nine months ended September 30, 2024, the net loss was $10.586 million, compared to $12.447 million for the same period in 2023.
• The company's cash and cash equivalents stood at $9.162 million as of September 30, 2024.
• Tenon Medical has an accumulated deficit of $65.7 million as of September 30, 2024.
• The company believes its current cash will not be sufficient to meet obligations for the next 12 months and plans to raise additional capital.
• The company completed a 1-for-8 reverse stock split on September 6, 2024, and a 1-for-10 reverse stock split on November 2, 2023.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including declining revenue, high operating expenses, and a going concern warning. While the company has raised capital, the overall outlook is negative due to the uncertainty of future revenue and the need for further financing.

Positives

• The company's net loss decreased for both the three and nine months ended September 30, 2024, compared to the same periods in 2023.
• Operating expenses decreased in Q3 2024, indicating cost management efforts.
• Cash and cash equivalents increased significantly due to financing activities.
• The company successfully raised capital through various means, including preferred stock issuances and warrant exercises.

Negatives

• Revenue decreased in Q3 2024 compared to Q3 2023, primarily due to a decrease in surgical procedures.
• Gross profit decreased in Q3 2024 compared to Q3 2023.
• The company has an accumulated deficit of $65.7 million.
• The company's current cash is not expected to be sufficient to meet obligations for the next 12 months.
• The company has a material weakness in internal controls due to a lack of segregation of duties.

Risks

• The company faces substantial doubt about its ability to continue as a going concern for the next 12 months.
• The company's future revenue is uncertain, and it may not be able to achieve profitability.
• The company may not be able to raise additional capital on acceptable terms or at all.
• The company's sales and marketing efforts may be negatively impacted by the restructured sales operation and reimbursement challenges.
• The company's internal controls are not effective, which could lead to errors in financial reporting.

Future Outlook

The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations and working capital requirements. The company expects to incur additional operating losses and negative cash flows from operations in the foreseeable future.

Management Comments

• Management believes that the company's existing cash and cash equivalents will not be sufficient to fund its operating expenses and working capital requirements through at least the next 12 months.
• Management plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations.
• Management believes that there is substantial doubt in the company's ability to continue as a going concern for the next twelve months from the issuance of these consolidated financial statements.

Industry Context

The company operates in the competitive medical device industry, specifically focusing on sacroiliac joint fusion. The company's performance is affected by factors such as reimbursement, competition, and the adoption of new technologies. The company is working to establish its product in the market and gain wider clinician adoption.

Comparison to Industry Standards

• Tenon Medical's revenue of $887,000 for Q3 2024 is relatively low compared to established medical device companies in the orthopedic space, such as Globus Medical (GMED) which reported $304.5 million in net sales for Q3 2024.
• The company's gross margin of 47% in Q3 2024 is lower than the industry average for medical device companies, which often exceeds 60%. Companies like Stryker (SYK) report gross margins around 65-70%.
• Tenon's operating expenses as a percentage of revenue are very high, indicating a need for greater efficiency and scale. Larger companies in the space, such as Medtronic (MDT), have much lower operating expense ratios due to their scale and established infrastructure.
• The company's reliance on external financing and its going concern uncertainty are significant risks compared to more established and profitable competitors.
• The company's focus on a specific niche, the SI joint fusion market, may limit its growth potential compared to companies with broader product portfolios.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers (clinicians) may be impacted by the company's ability to provide consistent product supply and support.
• Suppliers may face uncertainty regarding future orders and payments.
• Creditors face the risk of non-payment if the company is unable to raise sufficient capital.

Next Steps

• The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations.
• The company will continue to focus on the commercialization of The Catamaran System.
• The company will continue to monitor and address the material weakness in internal controls.

Key Dates

Keywords

medical devices, sacroiliac joint fusion, Catamaran System, surgical implants, revenue, net loss, operating expenses, capital raise, reverse stock split, financial results